NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LLY

Lilly(Eli) & Co

Jul 14 • 11:55AM ET

794.66

Dollar change +1.65
Percentage change 0.21	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: NVO JNJ ABBV MRK AZN AMGN PFE SNY BMY GSK

| Held by: VTI VOO SPY IVV VUG XLV VIG IWF QUAL VHT

Scroll to Statements

Index	S&P 500	P/E	65.83	EPS (ttm)	12.07	Insider Own	10.35%	Shs Outstand	948.10M	Perf Week	2.82%
Market Cap	753.12B	Forward P/E	26.65	EPS next Y	29.82	Insider Trans	-0.89%	Shs Float	849.66M	Perf Month	-1.73%
Enterprise Value	788.50B	PEG	1.57	EPS next Q	5.55	Inst Own	73.70%	Short Float	0.91%	Perf Quarter	10.23%
Income	11.11B	P/S	15.37	EPS this Y	67.68%	Inst Trans	0.99%	Short Ratio	1.98	Perf Half Y	0.94%
Sales	49.00B	P/B	47.79	EPS next Y	36.92%	ROA	14.49%	Short Interest	7.71M	Perf YTD	2.93%
Book/sh	16.63	P/C	233.84	EPS next 5Y	41.91%	ROE	77.73%	52W High	972.53 -18.29%	Perf Year	-15.44%
Cash/sh	3.40	P/FCF	201.56	EPS past 3/5Y	24.14% 18.77%	ROIC	22.10%	52W Low	677.09 17.36%	Perf 3Y	142.31%
Dividend Est.	6.24 (0.79%)	EV/EBITDA	36.59	Sales past 3/5Y	16.73% 15.08%	Gross Margin	81.70%	Volatility	2.24% 2.29%	Perf 5Y	376.56%
Dividend TTM	5.60 (0.70%)	EV/Sales	16.09	EPS Y/Y TTM	80.73%	Oper. Margin	40.25%	ATR (14)	18.36	Perf 10Y	820.27%
Dividend Ex-Date	Aug 15, 2025	Quick Ratio	1.06	Sales Y/Y TTM	36.38%	Profit Margin	22.66%	RSI (14)	56.43	Recom	1.53
Dividend Gr. 3/5Y	15.21% 15.05%	Current Ratio	1.37	EPS Q/Q	23.46%	SMA20	1.17%	Beta	0.44	Target Price	988.17
Payout	44.39%	Debt/Eq	2.44	Sales Q/Q	45.17%	SMA50	3.32%	Rel Volume	0.46	Prev Close	793.01
Employees	47000	LT Debt/Eq	2.19	Earnings	Aug 07 BMO	SMA200	-2.30%	Avg Volume	3.90M	Price	794.66
IPO	Jul 09, 1970	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.51% 0.48%	Trades		Volume	721,259	Change	0.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Downgrade	Erste Group	Buy → Hold
Apr-28-25	Downgrade	HSBC Securities	Buy → Reduce	$1150 → $700
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$975
Dec-10-24	Resumed	BofA Securities	Buy	$997
Nov-15-24	Initiated	Wolfe Research	Outperform	$1000
Oct-17-24	Initiated	Bernstein	Outperform	$1100
Sep-13-24	Resumed	Citigroup	Buy	$1060
Aug-12-24	Upgrade	Deutsche Bank	Hold → Buy	$1025
Feb-21-24	Downgrade	DZ Bank	Buy → Hold	$820
Feb-16-24	Reiterated	Morgan Stanley	Overweight	$805 → $950
Dec-21-23	Downgrade	Daiwa Securities	Buy → Outperform	$660 → $610
Nov-09-23	Initiated	Deutsche Bank	Hold	$535
Oct-20-23	Resumed	UBS	Buy	$612 → $710
Aug-09-23	Upgrade	Jefferies	Hold → Buy	$408 → $615
Jul-26-23	Reiterated	Citigroup	Buy	$360 → $525
Jul-14-23	Initiated	HSBC Securities	Buy	$560
May-24-23	Reiterated	UBS	Buy	$447 → $498
May-24-23	Reiterated	BofA Securities	Buy	$450 → $500
Mar-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$360 → $375
Mar-06-23	Initiated	Jefferies	Hold	$290

Show Previous Ratings

Today 11:22AM	Illimis secures funding for GAIA-based Alzheimers therapeutics (Pharmaceutical Technology)
10:23AM	MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth? (Zacks)
09:00AM	Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know (Zacks)
08:51AM	Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now. (Barrons.com)
06:04AM	Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research Report 2025 \| Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements (GlobeNewswire)
05:56AM	Loading…
05:56AM	GLP-1 Agonists Drug Pipeline Analysis Market Report 2025 \| Next-generation GLP-1 Agonists Pave the Way for Diabetes and Obesity Management (GlobeNewswire)
05:46AM	Obesity Drug Pipeline Analysis Report 2025 \| Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research (GlobeNewswire)
01:30AM	Biotech Stocks Are Ready to Rebound. 3 to Watch Now. (Barrons.com)
Jul-13-25 07:01AM	Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs. (The Wall Street Journal)
Jul-12-25 02:33PM	Eli Lilly and Company (LLY): I Would "Love" If Trump Praised The Company, Says Jim Cramer (Insider Monkey)
09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
06:40AM	3 Dividend Growth Stocks to Buy and Hold (Motley Fool)
Jul-11-25 08:47PM	Lightning Round: Huntington Ingalls is a buy, says Jim Cramer (CNBC TV)
04:56PM	Big pharma's multiple looming patent cliffs: What to know (Yahoo Finance Video)
03:52PM	Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth (GuruFocus.com)
08:54AM	Loading…
08:54AM	Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly? (Zacks)
04:01AM	Psoriatic Arthritis Market Report 2025-2035 \| Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma (GlobeNewswire)
04:00AM	Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill. (Barrons.com)
Jul-10-25 04:52PM	Integer Appoints Michael Coyle to Board of Directors (GlobeNewswire)
10:09AM	Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold? (Zacks)
09:41AM	Are Growth Stocks Back? 3 That Look Like Winners to Buy Now (MarketBeat)
09:34AM	Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:17AM	Big Pharma on the Clock as 200% Tariffs Loom (GuruFocus.com)
Jul-09-25 06:16PM	3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly (Motley Fool)
05:45PM	Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
11:48AM	Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity? (Zacks)
11:41AM	Wall Street waves off Trump's 200% pharma tariff threat (Yahoo Finance)
09:24AM	Merck Faces Multiple Challenges: Will It Steer Through Successfully? (Zacks)
09:19AM	Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck (Zacks)
07:29AM	Loading…
07:29AM	Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From? (The Wall Street Journal)
06:45AM	FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease (PR Newswire)
06:35AM	Stocks to Watch Wednesday: Freeport-McMoRan, UnitedHealth, Novo Nordisk (The Wall Street Journal)
06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire)
01:03AM	Eli Lilly (LLY) Announced Results for its Once-Weekly Insulin (Insider Monkey)
Jul-08-25 04:44PM	Don't Miss Out: 3 Blue-Chips Set to Pop This Earnings Season (MarketBeat)
03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com)
02:18PM	Trump Says Hell Set 50% Copper Tariff, Wait Year on Drug Levies (Bloomberg)
01:31PM	Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months (MarketWatch)
08:27AM	How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results? (Zacks)
07:49AM	Schizophrenia Market Research and Forecast Report 2025-2034 \| Emerging Therapies and Genetic Research Drive Growth with Bristol Myers Squibb, AstraZeneca, and Eli Lilly Leading (GlobeNewswire)
07:39AM	Anti-Obesity Drugs Market Research and Forecast Report 2025 \| Market to Surpass $120 Billion by 2034 - Increased Strategic Merger and Initiatives to Meet Rising Demand (GlobeNewswire)
06:03AM	Analysis: 'Trump Effect' website takes credit for US investment made under Biden (Reuters)
04:55AM	3 Underrated Dividend Growth Stocks to Buy and Hold for Years (Motley Fool)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily)
12:48PM	Prime Medicine stock soars amid gene editing sector momentum (Investing.com)
09:55AM	Novo and Lilly compete in India as obesity drugs demand hikes (Reuters Videos)
09:51AM	Smith Blasts Novo, Coloplast in Danish Life Science Rebuke (Bloomberg)
06:40AM	3 No-Brainer Stocks to Buy in July (Motley Fool)
04:00AM	GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down (Pharma Voice)
03:45AM	Better Growth Buy: Eli Lilly vs. Viking Therapeutics (Motley Fool)
Jul-06-25 07:05AM	2 Dividend Growth Stocks to Buy and Hold Forever (Motley Fool)
Jul-04-25 09:53AM	Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance? (Zacks)
03:22AM	UBS Sees Strong Sales Outlook for Eli Lilly's Zepbound and Mounjaro (Insider Monkey)
01:01AM	Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. (Barrons.com)
Jul-03-25 02:30PM	Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report (Benzinga)
08:48AM	Pfizer Trades Above 50-Day Average for a Month: Time to Buy? (Zacks)
08:20AM	Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth (Zacks)
Jul-02-25 09:30AM	Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy? (Zacks)
08:46AM	Will AbbVie's Acquisition Spree Aid Pipeline Growth? (Zacks)
05:43AM	Semaglutide Market Forecast Report 2025-2033 \| Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements (GlobeNewswire)
04:01AM	2 Growth Stocks to Buy Hand Over Fist in July (Motley Fool)
Jul-01-25 09:00AM	Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock (Zacks)
06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
06:20AM	Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? (Zacks)
06:06AM	How Novo Nordisk misread the US market for its weight loss sensation (Reuters)
Jun-30-25 05:08PM	FDA Approves Updated Label For Eli Lilly and Company (LLY)'s Amyvid To Support Alzheimer's Diagnosis (Insider Monkey)
04:09PM	Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? (Investor's Business Daily)
01:30PM	Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story (Barchart)
10:27AM	Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised) (Zacks)
08:18AM	RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimers market (Investing.com)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
Jun-28-25 06:47AM	Which Stock Will Dominate the Weight Management Market Through 2030? (Motley Fool)
Jun-27-25 11:10AM	NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? (Zacks)
10:10AM	Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed? (Zacks)
10:08AM	AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock (Zacks)
09:53AM	BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside (Investing.com)
Jun-26-25 11:12AM	VKTX Initiates Phase 3 Study on Obesity Candidate VK2735 (Zacks)
09:43AM	Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth? (Zacks)
07:31AM	Eli Lilly receives FDA approval for Amyvid label update (Pharmaceutical Technology)
02:59AM	5 Revealing Analyst Questions From Eli Lilly's Q1 Earnings Call (StockStory)
Jun-25-25 02:09PM	Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity (Investor's Business Daily)
12:20PM	Eli Lilly and Company (LLY) Is Going To Be A "Trillion-Dollar Market Cap," Says Jim Cramer (Insider Monkey)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
09:07AM	Novo Nordisk split puts Hims & Hers future in question (Yahoo Finance)
07:32AM	Citi bullish on Lilly as Orforglipron unlocks $40B+ obesity market (Investing.com)
06:05AM	3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow (Motley Fool)
05:56AM	United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption (GlobeNewswire)
03:47AM	Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates (Insider Monkey)
03:00AM	Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director (GlobeNewswire)
Jun-24-25 05:50PM	The Weight Loss Drug Market Has Gotten Messy. What to Know. (Barrons.com)
11:49AM	Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care (Zacks)
11:25AM	Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers? (Zacks)
10:25AM	Pfizer to Face Several Headwinds: Can It Successfully Navigate Them? (Zacks)
09:45AM	New AI Rollouts Signal Shift From Hype to Healthcare Reality (PR Newswire)
09:20AM	Will CVS Health's Formulary Move Boost Its Weight Management Program? (Zacks)
04:25AM	Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference (Insider Monkey)
12:01AM	Novo Nordisk Backs Away From Hims & Hers Partnership (The Daily Upside)
Jun-23-25 05:45PM	Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
04:15PM	Amgen Shares Fall on Weight-Loss Drug Tummy Troubles (Barrons.com)

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zakrowski Donald A	SVP, Finance, & CAO	May 27 '25	Sale	716.41	1,000	716,410	4,840	May 27 04:13 PM
Yuffa Ilya	EVP & President, LLY Int'l	May 14 '25	Sale	749.24	1,250	936,550	27,510	May 15 04:17 PM
Yuffa Ilya	Officer	May 14 '25	Proposed Sale	749.24	2,500	1,873,100		May 14 12:25 PM
DONALD ZAKROWSKI	Officer	Mar 13 '25	Proposed Sale	821.86	2,000	1,643,720		Mar 13 04:57 PM
Zakrowski Donald A	SVP, Finance, & CAO	Mar 13 '25	Sale	818.24	1,000	818,240	5,840	Mar 13 04:17 PM
LILLY ENDOWMENT INC	10% Owner	Mar 03 '25	Sale	928.76	220,000	204,326,151	96,016,978	Mar 04 04:00 PM
Dozier Eric	EVP, Chief People Officer	Mar 01 '25	Option Exercise	0.00	2,403	0	10,905	Mar 03 04:53 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Mar 01 '25	Option Exercise	0.00	2,837	0	41,009	Mar 03 04:51 PM
LILLY ENDOWMENT INC	10% Owner	Mar 03 '25	Proposed Sale	920.63	220,000	202,538,600		Mar 03 03:34 PM
LILLY ENDOWMENT INC	10% Owner	Feb 25 '25	Sale	903.07	225,000	203,190,794	96,236,978	Feb 26 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 24 '25	Sale	883.97	60,432	53,419,955	96,461,978	Feb 25 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 25 '25	Proposed Sale	881.40	225,000	198,315,000		Feb 25 03:05 PM
LILLY ENDOWMENT INC	10% Owner	Feb 21 '25	Sale	882.70	99,452	87,786,505	96,522,410	Feb 24 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 20 '25	Sale	877.99	14,685	12,893,353	96,621,862	Feb 21 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 19 '25	Sale	878.45	9,985	8,771,285	96,636,547	Feb 20 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 13 '25	Sale	879.52	35,446	31,175,396	96,646,532	Feb 14 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 13 '25	Proposed Sale	872.97	220,000	192,053,400		Feb 13 03:43 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 10 '25	Sale	863.21	5,000	4,316,065	117,888	Feb 12 04:15 PM
Skovronsky Daniel	Officer	Feb 10 '25	Proposed Sale	863.19	5,000	4,315,954		Feb 10 11:44 AM
LILLY ENDOWMENT INC	10% Owner	Feb 06 '25	Sale	874.13	210,000	183,567,262	96,681,978	Feb 07 04:00 PM
LILLY ENDOWMENT INC	10% Owner	Feb 06 '25	Proposed Sale	842.18	210,000	176,857,800		Feb 06 04:04 PM
Yuffa Ilya	EVP & President, LLY Int'l	Feb 01 '25	Option Exercise	0.00	3,269	0	23,071	Feb 04 04:28 PM
White Anne E.	EVP & Pres, Lilly Neuroscience	Feb 01 '25	Option Exercise	0.00	3,269	0	68,838	Feb 04 04:27 PM
Van Naarden Jacob	EVP & Pres., Lilly Oncology	Feb 01 '25	Option Exercise	0.00	3,023	0	14,868	Feb 04 04:26 PM
Skovronsky Daniel	EVP, CSO & Pres. LRL & LLY Imm	Feb 01 '25	Option Exercise	0.00	8,989	0	126,892	Feb 04 04:25 PM
Ricks David A	President, Chair, and CEO	Feb 01 '25	Option Exercise	0.00	26,561	0	496,385	Feb 04 04:24 PM
Rau Diogo	EVP & CIDO	Feb 01 '25	Option Exercise	0.00	3,269	0	14,370	Feb 04 04:23 PM
Jonsson Patrik	EVP&Pres, CardMetHlth, LLY USA	Feb 01 '25	Option Exercise	0.00	3,433	0	48,016	Feb 04 04:23 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Feb 01 '25	Option Exercise	0.00	2,861	0	33,479	Feb 04 04:21 PM
Hakim Anat	EVP, GC & Secretary	Feb 01 '25	Option Exercise	0.00	4,904	0	20,683	Feb 04 04:19 PM
Zakrowski Donald A	Officer	Nov 08 '24	Proposed Sale	803.38	900	723,042		Nov 08 04:54 PM
Zakrowski Donald A	SVP, Finance, & CAO	Nov 08 '24	Sale	803.38	900	723,042	5,480	Nov 08 04:18 PM
Montarce Lucas	EVP & CFO	Nov 01 '24	Option Exercise	0.00	1,074	0	11,541	Nov 05 04:15 PM
Hernandez Edgardo	EVP & Pres., Mfg. Operations	Nov 01 '24	Option Exercise	0.00	1,687	0	31,369	Nov 05 04:14 PM
Dozier Eric	EVP, HR & Diversity	Nov 01 '24	Option Exercise	0.00	1,534	0	8,724	Nov 05 04:13 PM
LILLY ENDOWMENT INC	10% Owner	Sep 03 '24	Sale	966.69	24,084	23,281,840	96,891,978	Sep 04 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Aug 27 '24	Sale	968.46	24,552	23,777,668	96,916,062	Aug 28 04:05 PM
Zakrowski Donald A	Officer	Aug 26 '24	Proposed Sale	950.00	750	712,500		Aug 26 04:47 PM
Zakrowski Donald A	SVP, Finance, & CAO	Aug 26 '24	Sale	950.00	750	712,500	6,380	Aug 26 04:21 PM
LILLY ENDOWMENT INC	10% Owner	Aug 22 '24	Sale	966.33	3,196	3,088,382	96,940,614	Aug 23 04:05 PM
LILLY ENDOWMENT INC	10% Owner	Aug 22 '24	Proposed Sale	951.97	215,000	204,673,550		Aug 22 12:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LLY

Lilly(Eli) & Co

Upgrade your FINVIZ experience